However, they are not effective in most cancers due to the mechanisms associated with their partial inhibition on mTORC1 and mTORC2 activation that plays a prominent role in driving resistance to Rapamycin in tumors through continued phosphorylation of Akt on Ser 473. The gene discussed is AKT1; the disease is cancer.